STOKROS

Stokros is a preclinical-stage biotechnology company dedicated to the discovery and development of small molecule modulators of lysosomal and mitochondrial ion channels. Founded on research from the University of Michigan, the company targets TRPML1 and the mitochondrial calcium uniporter (MCU) to treat neurodegenerative and lysosomal storage disorders. Their therapeutic strategy focuses on restoring cellular homeostasis by enhancing lysosomal function and regulating mitochondrial calcium levels. Stokros is currently advancing its lead candidates through preclinical studies for indications including Amyotrophic Lateral Sclerosis (ALS) and Parkinson's disease. The company aims to address the underlying cellular dysfunction common to many age-related and genetic neurological conditions.